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Background: Anti-TNF agents have proven efficacy in children with severe juvenile idiopathic arthritis (JIA) who are
unresponsive to standard therapy. Therefore pain reduction or elimination could be expected. The aim of this study
was to compare the pain experience in children with JIA treated with anti-TNF agents (n = 41) or non-biologic
standard treatment (n = 50).
Methods: All children completed a 2-week pain diary and, for children treated with anti-TNF agents, measures of
pain-coping and pain-specific beliefs. Parents rated the child’s level of functional disability. Clinical data were
collected from the pediatric rheumatologists.
Results: No significant differences were found between the anti-TNF group and non-biologic standard treatment
group for average pain score, number of children with daily pain reported in the pain diary, or level of functional
disability. Significantly more children in the anti-TNF group reported no pain at all. Children undergoing standard
treatment had significantly higher disease activity. Significant differences were found between the high pain
patients treated with anti-TNF agents and the rest of the anti-TNF group in regards to their pain-specific beliefs of
disability and harm, and the pain-coping strategy of catastrophizing.
Conclusion: These results indicate that a great proportion of children treated with anti-TNF agents respond well to
the treatment in regards to disease activity and pain, but pain was still a problem for a subgroup of children
though they were in remission with biological agents. More focus on pain management is needed.
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Coping, BeliefsBackground
Pain in children with juvenile idiopathic arthritis (JIA) is
more prevalent than previously recognized and with a
high daily prevalence [1-3]. Low-dose methotrexate, a
disease-modifying antirheumatic drug (DMARD), is con-
sidered a first line treatment after the failure of nonsteroi-
dal anti-inflammatory drugs (NSAIDs) and provides some
improvement in 60-70% of patients [4-6]. With the advent
of biological anti-tumor necrosis factor (anti-TNF) agents
the treatment options for JIA have improved markedly.
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reproduction in any medium, provided the orbeen reported to be efficacious in controlled studies
[7-12]. Reducing pain is one of the major treatment goals,
but only a few studies on the effect of anti-TNF agents
have reported pain as an outcome measure, and those that
do use only a single pain measure [7,11-14]. Although
anti-TNF agents do reduce and eliminate disease activity
and pain in many patients some patients still experience
incomplete pain control [15].
In addition to disease activity, multiple factors contrib-
ute to the pain experienced by children with JIA [16-20].
Possible mediators of the pain experience in children are
pain-coping strategies and pain-specific beliefs [21-23].
Coping is thought to be influenced by a person’s beliefs
about a stressor such as pain. A person’s beliefs are defined
as “assumptions about reality which serve as a perceptuall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.












Age (year): mean (S.D.) 11.8 (2.0) 13.8 (2.4) Z = −3.79 <0.001
Gender (male) 9 (18.0%) 12 (29.3%) χ2(1) = 1.04 0.31
JIA subtype: χ2(6) = 13.0 0.04
Systemic arthritis 5 (10.0%) 9 (22.0%)
Oligoarthritis persistent 11 (22.0%) 1 (2.4%)
Oligoarthritis extended 9 (18.0%) 9 (22.0%)
Polyarthritis
(RF-negative)
22 (44.0%) 17 (41.5%)
Polyarthritis
(RF-positive)
0 (0.0%) 1 (2.4%)
Psoriatic arthritis 1 (2.0%) 2 (4.9%)
Enthesitis-related
arthritis
0 (0.0%) 2 (4.9%)
Data on subtype n.a. 2 (4.0%)
Disease duration (year):
mean (S.D.)a
5.2 (3.6) 8.0 (3.6) Z = −3.23 0.001
Current use of
medication:
NSAID use: 41 (82.0%) 17 (41.5%) χ2(1) = 14.31 <0.001
Use of other
analgesics:
10 (20.0%) 15 (36.6%) χ2(1) = 2.33 0.13








aDisease duration was defined as the time from the onset of the symptoms to
the participation in the study.
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Primarily coping, but recently beliefs, has been investi-
gated in children with arthritis [17,21-23,25,26].
In our previous studies, we discovered that a high-pain
group consisting of children with a greater pain experi-
ence and lower disease activity compared to the median
values of the total group of patients differed significantly
from the remaining sample [21-23]. The high-pain group
tended to use the pain-coping strategies of distraction
and positive self-statements less and catastrophizing
more than the remaining sample of JIA children, and
they believed themselves to be more functionally im-
paired, that pain signifies danger, and that they have less
control over their pain compared to the remaining sam-
ple [21,22]. For the beliefs of harm and disability the dif-
ferences were consistent over a 2-year period [23].
Aim
Few studies have examined pain experience in children
treated with anti-TNF agents and only with a single-pain
measure [7,11-14]. The purpose of the present study was
to compare children receiving anti-TNF agents to chil-
dren receiving standard treatment in regards to pain ex-
perience on a daily basis for 2 weeks, disease activity,
and functional disability. We hypothesized that the chil-
dren in the anti-TNF agent group, because of the effect-
ive treatment, would experience less pain, lower level of
functional disability, and less disease activity compared
to a standard treatment group.
Our clinic has experience with children who respond
well to anti-TNF treatment in regards to measurable dis-
ease activity but still report frequent and significant pain.
Thus, we also explored differences in the use of pain-
coping and pain-specific beliefs in a subgroup of chil-
dren with pain treated with anti-TNF agents compared
to pain-free children in the treatment group. Based on
previous research, we hypothesized that the children ex-
periencing pain would express more maladaptive pain-
coping strategies and pain-specific beliefs.
Methods
Participants
Children treated at the Pediatric Rheumatology Clinic,
Aarhus University Hospital, and one of their parents
were invited to participate. Inclusion criteria were a con-
firmed JIA diagnosis according to ILAR criteria [27], age
8–17 years, lack of comorbidity with other chronic diseases,
and ability to speak fluent Danish.
Standard treatment group
During the period from September 2002 to February 2003,
all 67 children who met the criteria for inclusion in the
standard treatment group were invited to participate in the
study. Sixty-four children, each with one of their parents,agreed to participate in the study. Eighteen of the children
received methotrexate (36%) (Table 1). Four children who
received anti-TNF agents in the period following inclusion
of the standard treatment group were excluded from the
standard treatment group. When data was collected for
the anti-TNF agent group these four children completed
the measures again and were included in the anti-TNF
group. Ten children had incomplete diaries and were ex-
cluded from the analysis. The final sample consisted of 50
children (response rate = 75%). Results based on the data
from this sample were published previously [21,23].Anti-TNF group
An additional criterion for inclusion in the anti-TNF agent
group was current or previous treatment with anti-TNF
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February 2008 all 51 children who met the criteria for
inclusion in the anti-TNF agent group were invited to
participate in the study. Fifty children, each with one of
their parents, agreed to participate in the study. Nine
children had incomplete diaries and were excluded from
the analysis. The final sample consisted of 41 children
(response rate = 80%). Thirty-one children were treated
with etanercept, 3 with adalimumab, and 3 with infliximab.
Four children had ended treatment with anti-TNF agents at
the time of inclusion (1 was treated with etanercept, 2 with
adalimumab, and 1 with infliximab; mean time since ending
treatment = 1.6 years, S.D. =1.5 years).
Procedure
Parents and children were recruited during routine visits
at the clinic. Data were collected from one parent accom-
panying the child to the clinic. If two parents accompanied
the child preference for participation was given to the
child’s primary caregiver. The child and parent completed
the questionnaires separately at the clinic. Before comple-
ting the questionnaires each child was examined by a
pediatric rheumatologist who registered the disease activ-
ity. The children completed a pain diary twice a day during
the 2 weeks following the completion of the question-
naires. The study was approved by the Ethical Review
Board, Central Denmark Region, Denmark and informed
consent was obtained from the parents.
Measures
Both the children and their parents completed several
questionnaires. Based on this study’s aims and hypothe-
ses, the following scales were included in the analyses:
Pain diary
The pain diary measuring the children’s pain experience
consisted of the Revised Faces Pain Scale (FPS-R) [28].
The FPS-R contains six faces with anchors at the two
ends, representing a scale from 0,“no pain” to 5, “worst
pain”. The children were instructed to measure their
current pain intensity every morning and evening over
the following 2 weeks. The parents were asked to help
the child remember the procedure, but to avoid influen-
cing the child’s pain assessment. The FPS-R has been
recommended for research use [29].
Childhood health assessment questionnaire
Parents assessed the child’s level of functional disability
with the Childhood Health Assessment Questionnaire
(CHAQ) [30]. The CHAQ consists of 30 items and as-
sesses the children’s performance over the past week on
a 3-point Likert scale in eight areas of daily living (i.e.
dressing and personal care, rising, eating, walking, hy-
giene, reach, grip, and activities). The CHAQ disabilityindex was calculated by averaging the 30 items (range 0 to
3). A higher disability index indicated greater functional
impairment. Chronbach's alpha was acceptable (=0.95).
Pain coping questionnaire
Four subscales were used from the Danish version of the
Pain Coping Questionnaire (PCQ) [31]: behavioral dis-
traction, cognitive distraction, positive self-statements,
and catastrophizing. The four subscales consist of 19
items. On a 5-point Likert scale, the children indicated
how often they used the strategies to cope with pain.
The Cronbach’s alpha internal consistency reliability co-
efficients for each of the subscales were in an acceptable
range (0.73-0.86).
Survey of pain attitudes
Three subscales were used from a revised version of the
Survey of Pain Attitudes (SOPA) [32] (SOPA children’s
version): control (belief in one’s personal control over
pain), disability (belief in oneself as unable to function
because of pain), and harm (belief that pain signifies
damage and that exercise and activity should be re-
stricted). The three subscales consisted of 26 items.
On a 4-point Likert scale, the children indicated how
much they agreed with statements about their pain
problem.
Cronbach’s alpha internal consistency reliability coeffi-
cients for the subscales of control and disability were ac-
ceptable (Cronbach’s alpha = 0.60-0.74). The Cronbach’s
alpha was 0.57 for the harm subscale, which was less
than 0.60 and therefore not considered acceptable.
Therefore, one item (“Pain does not necessarily mean
that my body is being harmed”) was omitted from the
subscale because of weak correlation with the other
items in the subscales. The Cronbach’s alpha of the sub-
scales were then recalculated and considered acceptable
(Cronbach’s alpha = 0.65).
Disease activity
A composite arthritis activity score as described previ-
ously [21] was calculated based on data registered by the
physician as the sum of the active joint score (zero active
joints = 0; 1–2 active joints = 1; 3–4 active joints = 2, >4
active joints = 3), morning stiffness (<15 minutes = 0;
15–30 minutes = 1, 30–60 minutes = 2; >60 minutes = 3),
and erythrocyte sedimentation rate (<15 mm/hour = 0;
15–25 mm/hour = 1; 25–40 mm/hour = 2; >40 mm/hour = 3).
Statistical analysis
All statistical analyses were performed using IBM SPSS
version 20.0 for Windows (IBMW SPSSW, IBM Corp.,
Armonk, New York). The alpha level was set at 0.05 for
all analyses. Mean substitution of the missing items was
Lomholt et al. Pediatric Rheumatology 2013, 11:21 Page 4 of 8
http://www.ped-rheum.com/content/11/1/21performed for the PCQ, and SOPA-C subscales. Number
of missing on the PCQ subscales were between 0.4%
(cognitive distraction subscale and positive self-
statements subscale) and 1.1% (behavioral distraction),
and for the SOPA subscales the number of missing were
between 2.0% (control subscale) and 3.1% (disability
subscale). The Kolmogorov-Smirnov test indicated that
the CHAQ, FPS-R, and disease activity score was non-
normally distributed and transformation was not pos-
sible. Differences between the groups were examined
using the chi-square test for categorical variables and
Mann–Whitney U Test for continuous variables. Effect
sizes were calculated as r for continues variables and
Phi for categorical variables [33]. Because of the effect-
ive treatment in the anti-TNF group we expected more
children in the anti-TNF group to be pain-free. The
group differences regarding pain intensity and func-
tional disability were analyzed both with and without
the pain-free children to investigate the pain intensity and
functional disability level in the children, who experienced
pain.
Differences between the treatment groups regarding
socio-demographic and disease-related variables were
analyzed. Variables with significant group differences
were adjusted for in a regression modeling and entered
as one block in the analyses. Because of the skewed dis-
tribution of the pain intensity score, the score was
transformed into two sets of categorical variables. The
first variables were defined as children reporting no pain
at all in the pain diary or children reporting pain. The
second variables were defined as either pain every day in
the pain diary or pain less than every day.Results
The demographic characteristics of the two groups are pro-
vided in Table 1 including statistically differences between
the treatment groups. A relatively high number of children
with systemic arthritis received anti-TNF treatment. All
children in this group had active arthritis and were
without systemic symptoms.Table 2 Differences in pain and health status of all participat
Standard treatmen
group (n = 50)
Mean (S.D.) Media
Arthritis activity: Composite disease activity score 2.8 (2.5) 2.00
Functional disability: CHAQ dis. index 0.25 (0.37) 0.10
Pain intensity: Mean pain diary score 0.86 (0.88) 0.60
Number (%)
Patients with no pain reported in the pain diary 1 (2.0%)
Patients with daily pain reported in the pain diary 12 (24.0%)Comparison of pain and health status of the treatment
groups
When analyzing all the participating children, children
treated with anti-TNF agents experienced the same pain
intensity and functional disability as children undergoing
standard treatment. This is shown in Table 2. However,
disease activity was significantly lower in the anti-TNF
group compared to standard treatment with a large ef-
fect size. Significant more children in the anti-TNF
group reported no pain at all and this result showed a
moderate effect size. No differences were found regard-
ing the number of children with daily pain.
When excluding children with no pain at all reported
in the diary from the analyses significant differences
were found between the standard treatment group and
anti-TNF group regarding disease activity and pain in-
tensity. As shown in Table 3 children in the anti-TNF
group had significant lower disease activity and this dif-
ference showed a large effect size. However, children in
the anti-TNF group reported significant more pain and
the effect size of the difference was moderate.
In logistic regression analyses the following variables
were entered as predictor variables, because of signifi-
cant treatment group differences in the previous ana-
lyses: treatment group, age, disease duration, subtype,
use of NSAIDs, and disease activity. For the categorical
variable of children reporting no pain in the diary, the
model containing the predictor variables was significant
(χ2(11) = 25.84, p = 0.007). The model as a whole ex-
plained between 27% (Cox & Snell R square) and 48%
(Nagelkerke R square) of variance and correctly classi-
fied 87% of cases. As shown in Table 4 none of the pre-
dictor variables made a unique significant contribution.
For the categorical variable of the patient reporting daily
pain, a test of the full model against a constant-only
model did not reach a significant level, indicating that
the predictors as a set could not reliably be distinguished
between the categories (χ2(11) = 10.78, p = 0.46). The
Cox & Snell R square of 12% and Nagelkerke R square
of 18% indicated a weak relationship between prediction
and grouping. Overall prediction success was 77%, anding children
t Anti-TNF agents
group (n = 41)
Group-differences
n Mean (S.D.) Median Mann–Whitney
U-test
p-values Effect sizes (r)
0.65 (1.00) 0.00 Z = −4.51 <0.001 0.47
0.30 (0.32) 0.10 Z = −0.01 0.99 0.001
1.03 (1.19) 0.69 Z = −0.49 0.62 0.05
Number (%) Chi2-test p-values Effect sizes (phi)
13 (31.7%) χ2(1) = 15.27 <0.001 0.41
12 (29.3%) χ2(1) = 0.32 0.64 0.06
Table 3 Differences in pain and health status of children with pain reported in the pain diary
Standard treatment
group (n = 49)
Anti-TNF agents
group (n = 28)
Group-differences
Mean (S.D.) Median Mean (S.D.) Median Mann–Whitney
U-test
p-values Effect sizes (r)
Arthritis activity: composite disease activity score 2.90 (2.53) 2.00 0.68 (0.99) 0.00 Z = −3.95 <0.001 0.45
Functional disability: CHAQ dis. index 0.26 (0.38) 0.10 0.27 (0.31) 0.18 Z = −0.95 0.34 0.04
Pain intensity: mean pain diary score 0.88 (0.88) 0.61 1.50 (1.16) 1.34 Z = −2.57 0.01 0.29
Lomholt et al. Pediatric Rheumatology 2013, 11:21 Page 5 of 8
http://www.ped-rheum.com/content/11/1/21as shown in Table 4 none of the variables made a signifi-
cant contribution to prediction.
Comparing children with pain and pain-free children in
the anti-TNF agent group
A subgroup of children in the anti-TNF agent group (n = 28)
who reported pain in the pain diary was compared with
pain-free children in the anti-TNF agent group (n = 13). No
differences were found between the two pain subgroups in
regards to disease activity and age. The female: male gender
ratio in the pain-free subgroup was 1.17:1, compared to
3.67:1 for the subgroup with pain.
As shown in Table 5 the subgroup with pain tended to
use the pain-coping strategy of catastrophizing more
than the pain-free children in the treatment group. This
difference was significant and with a moderate effectTable 4 Overview predictor variables in the logistic
analyses
Dependent variable: children reporting no pain in the diary or
children reporting pain
Predictor β S.E. Wald’s χ2 df p eβ (odds ratio)
Constant 0.37 2.50 0.02 1 0.88 1.45
Treatment
group
−2.22 1.35 2.71 1 0.1 0.11
Age −0.01 0.02 0.06 1 0.80 1.00
Disease duration −0.01 0.10 0.06 1 0.81 1.00
Use of NSAID −0.71 0.83 0.74 1 0.39 0.49
Disease activity −0.84 0.67 1.58 1 0.21 0.43
Subtype 0.10 6 1.00
Dependent variable: children reporting daily pain in the diary or
not
Predictor β S.E. Wald’s
χ2
df p eβ (odds ratio)
Constant −2.664 2.065 1.663 1 .197 .070
Treatment
group
−1.436 .806 3.177 1 .075 .238
Age .002 .011 .030 1 .863 1.002
Disease duration -.003 .007 .262 1 .609 .997
Use of NSAID 1.157 .698 2.744 1 .098 3.180
Disease activity .114 .146 .606 1 .436 1.120
Subtype 2.411 6 .878size. The pain subgroup was also significantly more
likely to believe that pain signifies damage, and that they
were unable to function because of pain. These diffe-
rences showed moderate effect sizes.
Discussion
On average, the children treated with anti-TNF agents in
this 2-weeks diary study reported low pain, but contrary
to our hypotheses no differences were found between
the groups in terms of functional status and the average
pain experience over 2 weeks. The socio-demographic
and disease-related variables did not account for the dif-
ference or lack of difference between the pain variables.
Our results indicate that the majority of the children
treated with anti-TNF agents did respond well to the
treatment regarding disease activity, which was signifi-
cantly lower compared to children in standard treat-
ment, and a higher amount of children in the anti-TNF
group (almost 1/3) had no pain at all in 2 weeks. How-
ever 29% of the children treated with anti-TNF agents
reported pain on a daily basis despite treatment with
anti-TNF agents. To the best of our knowledge no previ-
ous studies have assessed pain frequency solely in chil-
dren treated with anti-TNF agents. In two diary studies
with children with arthritis 17% [34] and 39% [1]
reported pain on a daily basis. However, besides from
only including a subsample of children treated with anti-
TNF agents (about a quarter of the children were treated
with anti-TNF agents), the pain assessment method was
different from ours in the first study, and in the second
study only children diagnosed with polyarticular arthritis
were included, which makes meaningful comparisons
between the studies difficult.
When excluding the pain-free children from the ana-
lyses the difference between the treatment groups re-
garding disease activity maintained, but despite the
lower disease activity, the children in the anti-TNF agent
group experienced significant higher pain intensity. The
lack of association between disease activity and the level
of experienced pain has been found in other studies as
well. In a recent study with 2795 adults with arthritis,
75%-82% reported a pain level of moderate to severe,
though they rated their arthritis as somewhat to com-
pletely controlled [35]. In our previous study no changes
Table 5 Comparison of pain-coping and pain-specific beliefs in children with and without pain in anti-TNF treatment
Anti-TNF agents group
Subgroup with pain (n = 28) Pain-free subgroup (n = 13) Group differences
Mean (S.D.) Median Mean (S.D.) Median Mann–Whitney U Test p-values Effect sizes (r)
Pain-coping strategies
Behavioural distraction 2.94 (0.86) 2.70 3.02 (1.01) 3.40 Z = −0.62 0.54 0.10
Cognitive distraction 3.27 (0.93) 3.30 2.88 (1.03) 3.00 Z = −1.04 0.30 0.16
Positive self statements 2.91 (0.96) 3.10 2.83 (1.19) 2.60 Z = −0.07 0.94 0.01
Catastrophizing 1.99 (0.93) 1.63 1.43 (0.70) 1.20 Z = −2.03 0.04 0.32
Pain-beliefs
Control 2.84 (0.57) 2.89 2.83 (0.71) 3.00 Z = −0.12 0.91 0.02
Disability 2.69 (0.84) 2.56 1.96 (0.56) 1.89 Z = −2.68 0.007 0.42
Harm 3.38 (0.74) 3.50 2.81 (0.55) 2.83 Z = −2.55 0.01 0.40
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dren over a 2-years period even though the disease ac-
tivity was significantly reduced over the 2 years [23]. In
other studies however a strong association between dis-
ease activity and pain intensity has been demonstrated
[16,17,36,37]. However, with the use of multivariate statis-
tical methods, the severity of the disease has been shown
to predict only a small to medium part of the variance in
pain intensity reported by the children [18-20].
There are several possible reasons why pain persists in
the absence of significant disease activity. Central sensi-
tization causing hyperalgesia may be a biological factor af-
fecting the pain experience in children with JIA. We and
others have found significantly reduced pain threshold
and pain tolerance in children with arthritis compared
with healthy schoolchildren [22,38-40], which supports
the theory that chronic pain conditions may cause central
sensitization [41,42]. The amount of pain experienced by a
child with JIA may independently of the inflammatory dis-
ease be modulated by psychological and social factors as
well [43,44]. Studies have found that parental factors as
the parent’s pain history [45], personality profile [46], and
family function [47,48] may have an impact on the child’s
pain experience. Beside’s pain coping and pain-specific be-
liefs the child’s self-efficacy for managing the disease
[49-51] and emotional wellbeing [1,47,52,53] has been re-
lated to the child’s pain experience as well.
Our second hypothesis was confirmed: children treated
with anti-TNF agents, who reported pain in the diary
tended to use the pain-coping strategy of catastrophizing
more, they were significantly more likely to believe that
pain signifies damage, and that they were unable to func-
tion because of pain, than the pain-free children in the
treatment group. The proportion of girls in the pain sub-
group was larger than in the pain-free subgroup. Girls
tend to experience more pain [54,55] and more frequently
use the pain-coping strategy of catastrophizing than boys
[55,56]. Differences in the gender ratio could have animpact on the difference between the subgroups. However,
the result is similar to our previous findings with children
experiencing high pain despite low disease activity [21,22].
Based on the design of this and our previous studies a
causal relationship between pain cognitions and pain ex-
perience cannot be inferred. In a study with adult chronic
pain patients, changes in the pain beliefs of control, dis-
ability, and harm, pain catastrophizing, and self-efficacy
for managing pain mediated the effects of cognitive beha-
vioral therapy (CBT) on pain, and thus indicates that pain
cognitions are influencing pain experience [57]. There is a
need of further intervention studies to test whether these
mechanism apply for children with JIA.
To the best of our knowledge, this study is the first to
investigate daily pain experience in children treated with
anti-TNF agents, and to compare the pain scores with
pain reported by children receiving standard treatment.
However, some limitations exist in the interpretation of
the results of the present study. First, data from the
treatment groups was collected on two occasions, and
we are aware that the children are not clinically compa-
rable. The children included in the anti-TNF group have
most often started anti-TNF treatment because of ineffi-
cacy or intolerance to the DMARD therapy. However,
the attitude towards and use of analgesia and intra-
articular steroid injections did not change in the clinic
in the period between the data collections. Second, the
disease activity index has not been validated in a larger
patient population. However, the disease activity score
used in this publication was also used in our previous,
related publications [21,23]. We therefore found it most
reasonable to use this scoring method in the present
paper since the cohort of children receiving standard
treatment was ascertained from the previous investiga-
tions. The currently used activity score Juvenile Arthritis
Disease Activity Score (JADAS) [58], now being an ac-
cepted method of evaluating disease activity for children
with JIA, was not implemented when our study was star-
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intensity score we had to create categorical variables
from the continuous scale to control for treatment
group differences regarding pain in regression analyses.
Fourth, the cross-sectional design of the study does not
allow the inference of causal relationships.
Conclusions
In summary, significant conclusions can be drawn from
our results. A large proportion of children treated with
anti-TNF agents respond well to the treatment both in
regards to pain and disease activity. But for a subgroup of
these children pain is still a problem even though the dis-
ease is well-controlled. Further studies to investigate the
characteristics of this subgroup are needed. More know-
ledge about predictors of ongoing pain despite reduced
disease activity may help detecting the children early in
the treatment course and provide these children with ap-
propriate interventions. Psychological interventions may
contribute to diminish pain complaints and improve qual-
ity of life in children with JIA who are continuing to re-
port pain despite appropriate medical treatment.
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